Vistin Pharma is strongly committed to maintaining an open dialogue with our shareholders, potential investors, analysts, investment banks and the financial markets.

Our goal is for the share price to reflect the underlying value of the company by providing all price-relevant information to the market.
Last updated 29.03 2022 11:00
Nok 16,80
Since open-0,30 (-1.70%)
Since previous close +0,44 (+2.60%)

8 reasons for investing in Vistin Pharma ASA.

Leading Producer
Amongst Top 5 producers of metformin HCl globally
High Quality Reputation
Leading reputation as producer of high quality APIs with strong track record of customer delivery
Attractive Market Dynamics
Established position in growing metformin market
Diverse Client Portfolio
Established client base comprising mix of Big Pharma and leading generics players
Sustained Revenue Growth
Strong growth profile with double digit revenue growth in the last 5 years
Advanced Manufacturing Facilities
State of the art and dedicated manufacturing facility with potential for further expansion
Strong Leadership
Experienced management team with a strong track record
A Front-runner
Leading the ESG culture in the industry

Annual General Meeting 2026

Download resources

Quarterly Results

Annual Reports

Other downloads

Investor calendar

12.2.26
Q4 2025 Quarterly report
24.4.26
2025 Annual Report
24.4.26
Q1 Quarterly report
20.5.26
Annual General Meeting
20.8.26
Q2 and Half-Yearly report
29.10.26
Q3 Quarterly Report

Main shareholders

Per 30th June 2026

NAME

SHAREHOLDING

% SHARE

1
INTERTRADE SHIPPING AS*
14 509 280
32,70 %
2
HOLMEN SPESIALFOND
4 371 558
9,90 %
3
PACTUM VEKST AS*
2 991 773
6,70 %
4
MP PENSJON PK
1 719 848
3,90 %
5
SURFSIDE HOLDING AS
1 552 960
3,50 %
6
HENRIK MIDTTUN HAAVIE
796 410
1,80 %
7
STORKLEIVEN AS
751 000
1,70 %
8
AUGUST RINGVOLD AGENTUR AS
750 315
1,70 %
9
LUCELLUM AS
733 000
1,70 %
10
IVAR LØGES STIFTELSE
540 000
1,20 %
11
CORTEX AS
508 989
1,20 %
12
SANDEN EQUITY AS
500 000
1,10 %
13
DNB BANK ASA
497 600
1,10 %
14
DELTA AS
415 000
0,90 %
15
GINKO AS
400 000
0,90 %
16
MELESIO INVEST AS
397 110
0,90 %
17
NIELS CATO BECKETT AALL
301 658
0,70 %
18
NICOLAI ANDREAS EGER
266 102
0,60 %
19
SKANDINAVISKA ENSKILDA BANKEN AB
216 042
0,50 %
20
FRENICO AS
215 000
0,50 %
Total 20 largest shareholders
32 433 645
73,10 %
Other shareholders
11 910 947
26,90 %
Total number of shares
44 344 592
100%
* Board members of Vistin Pharma, or companies controlled by Board members
Vistin Pharma - Oslo Stock Exchange

Contact

Alexander Karlsen
CFO
Vistin Pharma ASA
alexander.karlsen@vistin.com
Alexander Karlsen